Company news

Formycon AG news in 2026

Formycon AG's news releases, calls and decks from 2026, newest first.

View company

Formycon and Biocelys Combine Complementary Development and Manufacturing Expertise in New Biosimilar Project FYB286

October 21, 2026

Formycon and Zydus: FYB206 Becomes First Publicly Announced Keytruda® Biosimilar Accepted for Review by FDA

October 13, 2026

Formycon Optimizes Biosimilar Development with AI-Powered Technologies: Digital Solutions Enhance Development Efficiency as Part of the FYB4GROWTH Strategy

October 6, 2026

Formycon sets Benchmark in Biosimilar Development: Scientific Foundation of the innovative Development Program for FYB206 published in the Journal BioDrugs

September 22, 2026

Formycon reports key operational achievements in the first half of 2026 and significantly improves financial results year-on-year

August 12, 2026

Formycon invites to conference call on 2026 half-year results and announces participation in international investor conferences

August 5, 2026

Formycon AG and OneSource Specialty Pharma announce strategic Manufacturing Partnership for Biosimilars

July 14, 2026

Formycon AG Reports Results of Annual General Meeting 2026

June 10, 2026

Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026

May 28, 2026

Formycon AG: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements

May 22, 2026

Formycon invites to conference call on the results of the first quarter of 2026 and announces participation in international investor conferences

May 21, 2026

Formycon expands commercial portfolio: Aflibercept biosimilars Ahzantive® and Baiama® are now available in the European Union

May 19, 2026

Formycon reports successful financial year 2025 with important operational progress, growing market presence and strategic partnerships

April 22, 2026

Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026

April 20, 2026

Formycon announces improved preliminary figures for the 2025 fiscal year and sets date for the publication of the annual financial statements

April 15, 2026

Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer

March 19, 2026

Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025

March 18, 2026

Formycon AG publishes preliminary figures for the 2025 fiscal year

March 4, 2026

Formycon announces positive clinical data for Keytruda® biosimilar candidate FYB206 (pembrolizumab)

February 25, 2026

Lotus Pharmaceutical becomes commercialization partner for Formycon’s Keytruda® biosimilar candidate FYB206 across major parts of the Asia-Pacific Region

February 11, 2026

Decks in 2026